Osteopontin promotes the progression of gastric cancer through the NF-κB pathway regulated by the MAPK and PI3K

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 282-290

  Liu, Jie ^a   Liu, Qishen ^b   Wan, Yali ^a   Zhao, Zhigang ^a   Yu, Honggang ^c   Luo, Hesheng ^c   Tang, Zhongzhi ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^b Department of Gastroenterology Xianning Hospital   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Gastric cancer; MAPK; Metastasis; NF B; Osteopontin; PI3K

Indexed keywords

CASPASE 3; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UROKINASE; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GASTRIC CANCER CELL LINE; GASTRIC METASTASIS; GENE SILENCING; HUMAN; HUMAN CELL; MALE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STOMACH CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL MOTION; EXPERIMENTAL NEOPLASM; METABOLISM; PATHOLOGY; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; OSTEOPONTIN; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; STOMACH NEOPLASMS;

EID: 84902588313     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2393     Document Type: Article

References (28)

1. Prince CW, Oosawa T, Butler WT, et al: Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 262: 2900-2907, 1987.
2. Ramaiah SK and Rittling S: Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 103: 4-13, 2008.
3. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006.
4. Higashiyama M, Ito T, Tanaka E and Shimada Y: Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 14: 3419-3427, 2007.
5. Imano M, Satou T, Itoh T, et al: Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 13: 1577-1582, 2009.
6. Junnila S, Kokkola A, Mizuguchi T, et al: Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. Genes Chromosomes Cancer 49: 28-39, 2010.
7. Wu CY, Wu MS, Chiang EP, et al: Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56: 782-789, 2007.
8. Tang H, Wang J, Bai F, et al: Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem Cell Biol 85: 103-110, 2007.
9. Gong M, Lu Z, Fang G, Bi J and Xue X: A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 272: 148-159, 2008.
10. Wang ZM, Cui YH, Li W, Chen SY and Liu TS: Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells. Oncol Rep 25: 997-1003, 2011.
11. Ue T, Yokozaki H, Kitadai Y, et al: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79: 127-132, 1998.
12. Dai N, Bao Q, Lu A and Li J: Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology 72: 89-96, 2007.
13. Zhang X, Tsukamoto T, Mizoshita T, et al: Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer. Oncol Rep 21: 609-613, 2009.
14. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226, 2008.
15. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF and Giachelli CM: NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 141: 1083-1093, 1998.
16. Rangaswami H, Bulbule A and Kundu GC: Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 279: 38921-38935, 2004.
17. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004.
18. Philip S and Kundu GC: Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278: 14487-14497, 2003.
19. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278: 28593-28606, 2003.
20. Jain S, Chakraborty G and Kundu GC: The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res 66: 6638-6648, 2006.
21. Mi Z, Guo H, Wai PY, Gao C and Kuo PC: Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27: 1134-1145, 2006.
22. Shaulian E and Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136, 2002.
23. Lin YH and Yang-Yen HF: The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/ Akt signaling pathway. J Biol Chem 276: 46024-46030, 2001.
24. Lee KW, Kim SG, Kim HP, et al: Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 68: 1916-1926, 2008.
25. Chae S, Jun HO, Lee EG, et al: Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 35: 1409-1416, 2009.
26. He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25: 2192-2202, 2006.
27. Zhao B, Sun T, Meng F, et al: Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 137: 1061-1070, 2011.
28. Tang X, Li J, Yu B, et al: Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci 9: 55-66, 2013.